文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者抗VEGF注射后失访研究

Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
PubMed 文献 · JAMA Ophthalmol · 2018-01-01

这项回顾性队列研究分析了9007例接受抗VEGF注射治疗的新生血管性年龄相关性黄斑变性(nAMD)患者,发现22.2%的患者失访(LTFU)。年龄较大、非白人种族、较低区域调整总收入、居住地距诊所较远以及单眼注射与失访 odds 升高相关。

要点

  • nAMD患者抗VEGF注射后失访率为22.2%。
  • 年龄>80岁、非白人种族、低收入、远距离及单眼注射者失访风险更高。
  • 需针对高风险患者设计干预以改善随访和视力结局。

核心结论

  • nAMD患者抗VEGF注射后失访率较高,并识别出多个与失访相关的风险因素。

主要发现

  • 9007例患者中2003例(22.2%)失访。
  • 与≤80岁患者相比,81-85岁(OR 1.58,95%CI 1.38-1.82,P<.001)、86-90岁(OR 2.29,95%CI 2.00-2.62,P<.001)和>90岁(OR 3.31,95%CI 2.83-3.86,P<.001)患者失访 odds 更高。
  • 与白人患者相比,非裔美国人(OR 1.47,95%CI 1.00-2.16,P=.05)、亚洲人(OR 2.63,95%CI 1.71-4.03,P<.001)、其他种族(OR 3.07,95%CI 1.38-6.82,P=.006)和种族未报告(OR 2.29,95%CI 1.96-2.68,P<.001)患者失访 odds 更高。
  • 与收入>$100 000者相比,区域调整总收入≤$50 000(OR 1.52,95%CI 1.30-1.79,P<.001)、$51 000-$75 000(OR 1.35,95%CI 1.17-1.56,P<.001)和$76 000-$100 000(OR 1.28,95%CI 1.08-1.50,P=.004)患者失访 odds 更高。
  • 与距诊所≤10英里者相比,居住21-30英里(OR 1.33,95%CI 1.05-1.69,P=.02)和>30英里(OR 1.55,95%CI 1.28-1.88,P<.001)患者失访 odds 更高;单眼注射者较双眼注射者失访 odds 更高(OR 1.44,95%CI 1.28-1.61,P<.001)。

关键数值与推荐

  • 失访定义为接受1次或以上注射后12个月内无后续随访就诊。

临床怎么用

  • 临床实践中应关注高龄、非白人种族、低收入、居住地远及单眼注射的nAMD患者,针对性设计干预以改善随访依从性。

局限性

  • 研究结果可能无法推广至其他医疗机构。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Loss to follow-up (LTFU) after anti-vascular endothelial growth factor (anti-VEGF) injections increases the risk of vision loss among patients with neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report rates of LTFU among patients with nAMD after anti-VEGF injections and to identify risk factors associated with LTFU in this population. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of data from 9007 patients who received anti-VEGF injections for treatment of nAMD was performed at an urban, private retina practice with multiple locations from April 1, 2012, to January 12, 2016. MAIN OUTCOMES AND MEASURES: Rates of LTFU after anti-VEGF injections. Loss to follow-up was defined as receipt of 1 or more injections with no subsequent follow-up visit within 12 months. RESULTS: Among the 9007 patients (mean [SD] age, 81.2 [8.8] years; 5917 [65.7%] female; 7905 [87.8%] white), 2003 (22.2%) were LTFU. Odds of LTFU were greater among patients 81 to 85 years of age (odds ratio [OR], 1.58; 95% CI, 1.38-1.82; P < .001), 86 to 90 years of age (OR, 2.29; 95% CI, 2.00-2.62; P < .001), and more than 90 years of age (OR, 3.31; 95% CI, 2.83-3.86; P < .001) compared with patients 80 years of age and younger. Odds of LTFU among African American patients (OR, 1.47; 95% CI, 1.00-2.16; P = .05), Asian patients (OR, 2.63; 95% CI, 1.71-4.03; P < .001), patients of other race (OR, 3.07; 95% CI, 1.38-6.82; P = .006), and patients of unreported race (OR, 2.29; 95% CI, 1.96-2.68; P < .001) were greater than odds of LTFU among white patients. Odds of LTFU were greater among patients with regional adjusted gross income of $50 000 or less (OR, 1.52; 95% CI, 1.30-1.79; P < .001), $51 000 to $75 000 (OR, 1.35; 95% CI, 1.17-1.56; P < .001), and $76 000 to $100 000 (OR, 1.28; 95% CI, 1.08-1.50; P = .004) compared with patients with incomes greater than $100 000. Odds of LTFU for patients living 21 to 30 miles (OR, 1.33; 95% CI, 1.05-1.69; P = .02) and more than 30 miles (OR, 1.55; 95% CI, 1.28-1.88; P < .001) from clinic were greater compared with patients who lived 10 miles or less from the clinic. Odds of LTFU were greater among patients who received unilateral injections (OR, 1.44; 95% CI, 1.28-1.61; P < .001) than among patients who received bilateral injections. CONCLUSIONS AND RELEVANCE: We found a high rate of LTFU after anti-VEGF injections among patients with nAMD and identified multiple risk factors associated with LTFU among this population. Although our results may not be generalizable, data on LTFU in a clinical practice setting are needed to understand the scope of the problem so that interventions may be designed to improve outcomes.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Obeid A, Gao X, Ali FS, et al. Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Anti-Vascular Endothelial Growth Factor Injections. JAMA Ophthalmol. 2018. PMID: 30352121. doi:10.1001/jamaophthalmol.2018.3578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。